ClinicalTrials.gg
CompletedNCT02681094Updated Oct 10, 2018Results posted

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

A Phase 3 interventional study of Dapagliflozin and Placebo for Dapagliflozin in Type 2 Diabetes Mellitus and Inadequate Glycaemic Control, sponsored by AstraZeneca. Completed at 110 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
905
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
21st of 180
905 · median 82
Started
2016
with 18 others
Phase 3
47 of 180
4 open now
Registered
75th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 19 that started in 2016, is one of 47 in phase 3, and was the 75th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Inadequate Glycaemic Control

Keywords

  • Diabetes Mellitus Type 2,
  • saxagliptin,
  • dapagliflozin,
  • metformin
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥18 years old at time of ;
  2. Patients with Type 2 diabetes mellitus (T2DM) defined as ≥7.5% to ≤10.0% at screening visit;
  3. Stable metformin therapy for at least 8 weeks prior to enrolment at a dose of ≥1500mg per day;
  4. ≤45.0kg/m2 at Enrolment visit;
  5. Fasting Plasma Glucose (FPG) ≤ 270mg/dl(15.0mmol/L) at the enrolment visit;
  6. For Females Only: Women of (WOCBP) must be using an acceptable method of to avoid pregnancy throughout the study and for at least 4 weeks after the last dose of study medication in such a manner that the risk of pregnancy is minimized.

Exclusion criteria

Exclusion Criteria:

  1. History of diabetes insipidus, Type 1 diabetes or Latent Diabetes of Adults, diabetic ketoacidosis or hyperosmolar nonketotic coma and Symptoms of poorly controlled diabetes that would preclude participation in this trial including but not limited to marked polyuria and polydipsia with greater than 10% weight loss during the 3 months prior to Enrolment (Visit 1), or other signs and symptoms.
  2. History of pancreatitis.
  3. Administration of any antihyperglycaemic therapy, other than metformin, for more than 14 days (consecutive or not) during the 8 weeks prior to enrolment
  4. Any use of DPP-4 inhibitor or SGLT-2 inhibitor within 8 weeks prior to enrolment.
  5. Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency and/or significant abnormal liver function, including patients with (ALT) and/or Aspartate transaminase (AST) ≥3x (Upper Limit of Normal)and/or Total ≥2.0x ULN. History of severe hepatobiliary disease or hepatotoxicity with any medication. Positive serologic evidence of current infectious liver disease, including patients who are known to be positive for Hepatitis viral antibody ImmunoglobulinM (IgM), surface antigen, and virus antibody.
  6. Moderate or severe impairment of renal function [defined as Estimated (eGFR) \<60milliLitre/min/1.73 m2 (estimated by Modification in Diet and Renal Disease (MDRD)) or serum creatinine ≥1.5mg/dL in males or ≥1.4mg/dL in females]. Conditions of congenital renal glucosuria, history of unstable or rapidly progressing renal disease.
  7. History of any disease or disorder which, in the opinion of the investigator, may put the patient at risk because of participation in the study, may influence the results, or may limit the patient's ability to participate in or complete the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
905 participants (actual)

Study arms

  • Active comparator
    Saxagliptin+Dapagliflozin+Metformin

    5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin

    Drug: Dapagliflozin · Drug: Saxagliptin

  • Active comparator
    Dapagliflozin+Saxagliptin placebo+Metformin

    5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo

    Drug: Dapagliflozin · Drug: Placebo for Saxagliptin

  • Active comparator
    Saxagliptin+Dapagliflozin placebo+metformin

    5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo

    Drug: Placebo for Dapagliflozin · Drug: Saxagliptin

Interventions

  • 5mg, orally, Green, plain, diamond-shaped, film-coated tablet

    Also known as: Forxiga

  • DrugPlacebo for Dapagliflozin

    Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet

  • 5mg, orally, Plain, yellow, biconvex, round, film-coated tablet

    Also known as: Onglyza™

  • DrugPlacebo for Saxagliptin

    Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c at Week 24

    To demonstrate the superiority of the change from baseline HbA1c achieved with the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually after 24 weeks. Results were presented for the modified full analysis set. Note: Baseline was defined as the last assessment on or prior to the date of the first dose of the study medication.

    Time frame: Baseline and week 24

Secondary outcomes

  1. Proportion of Participants Achieving HbA1c <7.0% at 24 Weeks

    To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually on proportion of participants achieving therapeutic glycaemic response after 24 weeks. Therapeutic glycaemic response was defined as an HbA1c value at Week 24 \<7.0% irrespective of whether participant received rescue medication. Risk difference for each treatment was calculated as adjusted response rate. Participants who did not had an HbA1c measurement at Week 24 were regarded as non-responders. Results were presented for the modified full analysis set.

    Time frame: Baseline and week 24

  2. Change in Fasting Plasma Glucose at 24 Weeks

    To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5mg to either agent individually on fasting plasma glucose after 24 weeks. Results were presented for the modified full analysis set.

    Time frame: Baseline and week 24

  3. Change in Total Body Weight at 24 Weeks

    To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to saxagliptin 5 mg on total body weight after 24 weeks. Results were presented for the modified full analysis set.

    Time frame: Baseline and week 24

07

Results

Posted Oct 10, 2018

Participant flow

The study was conducted at 119 sites in 6 countries: Canada, Czech Republic, Germany, Mexico, Russia, and United States (US). Approximately 900 participants were to be randomized. Participants with Type 2 Diabetes (T2DM) inadequately controlled on metformin alone were randomized in this study.

1 -Modified Enrolled Participants Set
Participant flow — 1 -Modified Enrolled Participants Set
MilestoneDapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Started293294296
Participants completed treatment period273276283
Completed256255243
Not completed373953
Withdrew: Participant decision7109
Withdrew: Adverse event1041
Withdrew: Severe non-compliance to protocol201
Withdrew: Lack of therapeutic response1514
Withdrew: Study-specific discontinuation criteria111320
Withdrew: Other667
Withdrew: No treatment given011
2 - Enrolled Participants Set
Participant flow — 2 - Enrolled Participants Set
MilestoneDapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Started301302302
Participants completed treatment period281284289
Completed261261248
Not completed404154
Withdrew: Participant decision7109
Withdrew: Adverse event1041
Withdrew: Severe non-compliance to protocol201
Withdrew: Lack of therapeutic response1514
Withdrew: Study specific discontinuation criteria141521
Withdrew: Other667
Withdrew: No treatment given011

Outcome measures

PrimaryChange From Baseline in HbA1c at Week 24

To demonstrate the superiority of the change from baseline HbA1c achieved with the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually after 24 weeks. Results were presented for the modified full analysis set. Note: Baseline was defined as the last assessment on or prior to the date of the first dose of the study medication.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Percentage (%)
Change From Baseline in HbA1c at Week 24
Percentage (%)Dapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Change From Baseline in HbA1c at Week 24-1.03 ± 0.0558-0.63 ± 0.0560-0.69 ± 0.0551
Statistical analysis
  • Dapagliflozin + Saxagliptin + Metformin vs Dapagliflozin + Metformin · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.40 · 95% CI -0.55 to -0.24
  • Dapagliflozin + Saxagliptin + Metformin vs Saxagliptin + Metformin · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.34 · 95% CI -0.50 to -0.19
SecondaryProportion of Participants Achieving HbA1c <7.0% at 24 Weeks

To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually on proportion of participants achieving therapeutic glycaemic response after 24 weeks. Therapeutic glycaemic response was defined as an HbA1c value at Week 24 \<7.0% irrespective of whether participant received rescue medication. Risk difference for each treatment was calculated as adjusted response rate. Participants who did not had an HbA1c measurement at Week 24 were regarded as non-responders. Results were presented for the modified full analysis set.

Time frame:
Baseline and week 24
Reported as:
Number · Participants
Proportion of Participants Achieving HbA1c <7.0% at 24 Weeks
ParticipantsDapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Proportion of Participants Achieving HbA1c <7.0% at 24 Weeks1246383
Statistical analysis
  • Dapagliflozin + Saxagliptin + Metformin vs Dapagliflozin + Metformin · Method of Zhang, Tsiatis, and Davidian · p = <0.0001 · Risk difference (rd): 19.8 · 95% CI 12.7 to 26.9
  • Dapagliflozin + Saxagliptin + Metformin vs Saxagliptin + Metformin · Method of Zhang, Tsiatis, and Davidian · p = 0.0018 · Risk difference (rd): 11.7 · 95% CI 4.4 to 19.1
SecondaryChange in Fasting Plasma Glucose at 24 Weeks

To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5mg to either agent individually on fasting plasma glucose after 24 weeks. Results were presented for the modified full analysis set.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Milligrams per deciliter (mg/dL)
Change in Fasting Plasma Glucose at 24 Weeks
Milligrams per deciliter (mg/dL)Dapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Change in Fasting Plasma Glucose at 24 Weeks-27.53 ± 2.1557-19.95 ± 2.1738-12.66 ± 2.1373
Statistical analysis
  • Dapagliflozin + Saxagliptin + Metformin vs Dapagliflozin + Metformin · Mixed Models Analysis · p = 0.0135 · Ls mean difference: -7.58 · 95% CI -13.59 to -1.57
  • Dapagliflozin + Saxagliptin + Metformin vs Saxagliptin + Metformin · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -14.88 · 95% CI -20.85 to -8.91
SecondaryChange in Total Body Weight at 24 Weeks

To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to saxagliptin 5 mg on total body weight after 24 weeks. Results were presented for the modified full analysis set.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Kilograms (Kg)
Change in Total Body Weight at 24 Weeks
Kilograms (Kg)Dapagliflozin + Saxagliptin + MetforminSaxagliptin + Metformin
Change in Total Body Weight at 24 Weeks-2.01 ± 0.1829-0.41 ± 0.1815
Statistical analysis
  • Dapagliflozin + Saxagliptin + Metformin vs Saxagliptin + Metformin · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.60 · 95% CI -2.11 to -1.09

Adverse events

Collected over From time of randomization, and throughout the treatment period and until end of treatment (Visit 5)/early termination + 4 days for non serious AEs and 30 days for SAEs.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin + Saxagliptin + Metformin1/293 (0.3%)7/293 (2.4%)41/293 (14%)
Dapagliflozin + Metformin2/293 (0.7%)8/293 (2.7%)39/293 (13.3%)
Saxagliptin + Metformin0/295 (0%)7/295 (2.4%)29/295 (9.8%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventDapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Cerebrovascular accidentNervous system disorders0/2932/2930/295
Angina unstableCardiac disorders1/2930/2930/295
Coronary artery diseaseCardiac disorders1/2930/2930/295
Myocardial infarctionCardiac disorders0/2931/2930/295
TachycardiaCardiac disorders0/2931/2930/295
Ventricular arrhythmiaCardiac disorders0/2931/2930/295
Radius fractureInjury, poisoning and procedural complications1/2930/2930/295
Road traffic accidentInjury, poisoning and procedural complications1/2930/2930/295
Sternal fractureInjury, poisoning and procedural complications1/2930/2930/295
Tendon ruptureInjury, poisoning and procedural complications0/2931/2930/295
Most frequent other events
Most frequent other events
EventDapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + Metformin
Glomerular filtration rate decreasedInvestigations12/29311/2935/295
Viral upper respiratory tract infectionInfections and infestations5/2939/2938/295
InfluenzaInfections and infestations3/2939/2933/295
Urinary tract infectionInfections and infestations7/2933/2935/295
PollakiuriaRenal and urinary disorders7/2931/2930/295
NauseaGastrointestinal disorders6/2935/2933/295
Upper respiratory tract infectionInfections and infestations3/2934/2936/295

Baseline characteristics

Full analysis set (FAS): All randomized participants who took at least 1 dose of study drug \& had baseline value for HbA1c. Analysis was based on randomized treatment. Modified FAS - all participants from FAS with the exception of participants from one site (United States; excluded due to serious Good Clinical Practice \[GCP\] violations).

Age, Continuous
Age, Continuous(Years)Dapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + MetforminTotal
Mean57.2 ± 10.6855.9 ± 10.9457.0 ± 9.9456.7 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + MetforminTotal
Female148137134419
Male142152157451
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + MetforminTotal
Hispanic or Latino999599293
Not Hispanic or Latino191194192577
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dapagliflozin + Saxagliptin + MetforminDapagliflozin + MetforminSaxagliptin + MetforminTotal
American Indian or Alaska Native1304
Asian99624
Native Hawaiian or Other Pacific Islander0000
Black or African American10172451
White265257258780
More than one race0000
Unknown or Not Reported53311
08

Study locations

110 sites
  • Research Site
    Saraland, Alabama 36571, United States
  • Research Site
    Fresno, California 93702, United States
  • Research Site
    Harbor City, California 90710, United States
  • Research Site
    Hawaiian Gardens, California 90716, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Montclair, California 91763, United States
  • Research Site
    Pomona, California 91767, United States
  • Research Site
    Spring Valley, California 91978, United States
  • Research Site
    Vallejo, California 94592, United States
  • Research Site
    Denver, Colorado 80220, United States
  • Research Site
    Northglenn, Colorado 80234, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Cooper City, Florida 33024, United States
  • Research Site
    Doral, Florida 33166, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Miami Lakes, Florida 33016, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Buford, Georgia 30518, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Hazel Crest, Illinois 60429, United States
  • Research Site
    New Orleans, Louisiana 70115, United States
  • Research Site
    Zachary, Louisiana 70791, United States
  • Research Site
    Biloxi, Mississippi 39531, United States
  • Research Site
    Florissant, Missouri 63031, United States
  • Research Site
    Albany, New York 12203, United States
  • Research Site
    Bronx, New York 10459, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Mooresville, North Carolina 28117, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Columbus, Ohio 43201, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    West Columbia, South Carolina 29169, United States
  • Research Site
    Dallas, Texas 75208, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Fort Worth, Texas 76132, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77036, United States
  • Research Site
    Houston, Texas 77040, United States
  • Research Site
    Odessa, Texas 79761, United States
  • Research Site
    Sugar Land, Texas 77479, United States
  • Research Site
    Waco, Texas 76710, United States
  • Research Site
    Salt Lake City, Utah 84102, United States
  • Research Site
    Norfolk, Virginia 23510, United States
  • Research Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Research Site
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • Research Site
    Brampton, Ontario L7A 3P1, Canada
  • Research Site
    Etobicoke, Ontario M9W 4L6, Canada
  • Research Site
    London, Ontario N5W 6A2, Canada
  • Research Site
    Scarborough, Ontario M1P 2T7, Canada
  • Research Site
    Sudbury, Ontario P3E 6C3, Canada
  • Research Site
    Toronto, Ontario M3J 2C5, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Levis, Quebec G6W 0M5, Canada
  • Research Site
    Mirabel, Quebec J7J 2K8, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
  • Research Site
    Saint-Marc-des-Carrieres, Quebec G0A 4B0, Canada
  • Research Site
    Ceske Budejovice, 370 01, Czechia
  • Research Site
    Chrudim III, 537 01, Czechia
  • Research Site
    Jilove u Prahy, 254 01, Czechia
  • Research Site
    Ostrava, 710 00, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Plzen, 301 66, Czechia
  • Research Site
    Praha - Klanovice, 190 14, Czechia
  • Research Site
    Praha 10, 100 00, Czechia
  • Research Site
    Praha 4, 140 46, Czechia
  • Research Site
    Praha 4, 149 00, Czechia
  • Research Site
    Praha 8, 181 00, Czechia
  • Research Site
    Uherske Hradiste, 686 01, Czechia
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Bünde, 32257, Germany
  • Research Site
    Essen, 45359, Germany
  • Research Site
    Giengen, 89537, Germany
  • Research Site
    Grossheirath, 96269, Germany
  • Research Site
    Hof, 95030, Germany
  • Research Site
    Hohenmölsen, 06679, Germany
  • Research Site
    Karlsruhe, 76199, Germany
  • Research Site
    Lichtenfels, 96215, Germany
  • Research Site
    Meine, 38527, Germany
  • Research Site
    Münster, 48153, Germany
  • Research Site
    Rehburg Loccum, 31547, Germany
  • Research Site
    Stolberg, 52222, Germany
  • Research Site
    Villingen-Schwenningen, 78048, Germany
  • Research Site
    Guadalajara, 44160, Mexico
  • Research Site
    Guadalajara, 44600, Mexico
  • Research Site
    Guadalajara, 44670, Mexico
  • Research Site
    Mexico, 03800, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    Monterrey, 64465, Mexico
  • Research Site
    Zapopan, 45116, Mexico
  • Research Site
    Arkhangelsk, 163001, Russian Federation
  • Research Site
    Ekaterinburg, 620039, Russian Federation
  • Research Site
    Ekaterinburg, 620219, Russian Federation
  • Research Site
    Izhevsk, 426063, Russian Federation
  • Research Site
    Kazan, 420008, Russian Federation
  • Research Site
    Moscow, 119991, Russian Federation

Showing the first 100 of 110 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jul 2017, 16 months.

Results were first posted in Oct 2018, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2016
First posted
Feb 12, 2016
StartActual
Feb 26, 2016
Primary completionActual
Jul 15, 2017
CompletionActual
Jul 15, 2017
Results first posted
Oct 10, 2018
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02681094
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 12, 2016
Start date
Feb 26, 2016
Primary completion
Jul 15, 2017
Completion
Jul 15, 2017
Results posted
Oct 10, 2018
Last update
Oct 10, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Saxagliptin

Start the discussion